Leqembi (lecanemab-irmb)
$1,923.39
We can help with your prescription. Read the “Prescription Guide”.
You can access this medicine even if it’s not approved in your country. Learn how.
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that responds against the amyloid-beta (Aβ) plaques prescribed to treat patients with Alzheimer’s disease who present mild-stage cognitive impairment or dementia1.
Buy Leqembi (lecanemab-irmb)
What is Leqembi (lecanemab-irmb) for?
Leqembi (lecanemab-irmb) is a prescription medicine used to treat patients with mild-stage cognitive impairment or dementia in Alzheimer’s disease[1].
How does Leqembi (lecanemab-irmb) work?
Leqembi (lecanemab-irmb) lessens the number of amyloid beta plaques in the brain which affects the loss of neurons. Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that selectively binds with the amyloid-beta (Aβ) aggregate forms, soluble and insoluble; as a result, the amyloid-betas (Aβ) are neutralized and eliminated[1].
Where has Leqembi (lecanemab-irmb) been approved?
Leqembi (lecanemab-irmb) was approved for patients with Alzheimer’s disease by:
- The Food and Drug Administration (FDA), USA on January, 2023[2].
References
- Full prescribing information [FDA]: Leqembi (lecanemab-irmb) (PDF)
Eisai inc., January 2023 - FDA grants accelerated approval for Alzheimer’s disease treatment
FDA, January 2023
| Single-dose vial x 500 mg/5 mL (100 mg/mL) | 1,923.39 |
|---|
Be the first to review “Leqembi (lecanemab-irmb)”
Related products
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Alzheimer's disease
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Reviews
There are no reviews yet.